Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)

Innovation Grants to Nurture Initial Translational Efforts (IGNITE Program)

A suite of early-stage therapy development funding programs called Innovation Grants to Nurture Initial Translational Efforts (IGNITE) is meant to serve a feeder program to the later-stage therapy development programs such as the Cooperate Research to Enable and Advance Translational Enterprises (CREATE) for Biologics and Blueprint Neurotherapeutics (BPN) Programs.

IGNITE program applications will be reviewed within the NINDS Scientific Review Branch and not at the Center for Scientific Review (CSR).

The next receipt date for IGNITE Funding Opportunities is June 17, 2020

 

Comparison of IGNITE Programs

IGNITE program applications will be reviewed within the NINDS Scientific Review Branch and not at the Center for Scientific Review (CSR).

Definitions for Key Terms

Application Support Library-IGNITE Example: Milestones

 

Use this chart to help you decide which program better suits your needs.

Grant Program Entry Criteria End Goal

PAR-18-761: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Novelty- significant improvement over existing therapies

Biological Rationale

Relevance for therapy development

Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled

PAR-18-762: Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

Novelty

Strong biological rationale and premise

Relevance for therapy development

Available test agent(s) or library

Testing funnel to triage candidates, a battery of assays and starting agents that are well profiled

 

PAR-18-763: Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

Translational rationale for the proposed model system, ex vivo system, or pharmacodynamic marker and evidence of value for future drug discovery/development Translationally relevant animal models, ex vivo systems, testing paradigms, and endpoints

 

Common to all three funding opportunities:

Timeline: 3 years total for both the R61 and R33 phases, with no more than 2 years in either phase.

Budget: Total direct costs may not exceed $750,000 for the entire 3-year project period, with no more than $499,000 in direct costs in any single year.